Resources

Watch PRI's Dr. Wayne Winegarden discuss the importance of improving competitions for biosimilars to increase access to these high value medications for more patients on two "Bending the Cost Curve" panel discussions hosted by State of Reform. https://youtu.be/oJTD34j-E-Y https://youtu.be/hu8sWIn3u_A...

A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute. “Cost effectiveness reports may provide precise estimates, but there is no reason to believe that these estimates accurately reflect the value of medicines,” said Dr. Wayne Winegarden, the brief’s author.  “The documented biases in their value assessments should raise serious concerns that...

Tearing down drug “rebate walls” that increase patient costs and block access to cheaper and often more effective medications would increase competition, lower out-of-pocket costs, and improve health outcomes, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click to download the brief “America’s patients are harmed because they do not benefit from large, fast-growing rebates when purchasing their medicines,” writes the brief’s author, Dr. Wayne Winegarden, director of PRI’s Center...

Dr. Henry Miller, PRI senior fellow in health care studies and former founding director of the FDA’s Office of Biotechnology, joins PRI's "Next Round" podcast with an update on efforts to develop vaccines and therapeutics to fight Covid-19.  He discusses how a transition between two presidential administrations will affect the work of the federal government in fighting Covid-19, whether a national mask mandate is a good idea, whether Governors like Gavin Newsom should initiate state-level reviews of potential vaccines, and...

A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute shows that counterfeit drugs put patients in harm’s way, hinder drug innovation, and lead to job losses. Proposals like drug importation or price controls, if implemented, would exacerbate the problem and result in more health and economic consequences. Click here to download the brief “Counterfeit drugs expose patients to potentially lethal contaminants, and may also increase public health risks by failing to effectively...

A new brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute found that reforms mandating drug rebates benefit patients rather than payers would lower overall health care costs and help patients with expensive out-of-pocket drug costs. Click here to download the brief “Ironically, the current drug concession system is raising patient costs,” write the briefs authors, Wayne Winegarden and Robert Popovian. “Mandating that all drug concessions must benefit the patients purchasing the medicines is a...

If you’ve ever had a medical procedure and received a large bill from your hospital because, unknown to you, one of your doctors was not in your insurance network – that’s the subject of this podcast. On "Next Round," PRI senior fellow Wayne Winegarden discusses his recently released study on “Surprise Medical Billing.” He explains how it happens, why it happens, and the reforms that could prevent it. https://youtu.be/G4BvoVHT4so...

As they approach the end of the Drug Pricing Maze, the Professor and Pete explore reforms to fix a broken system and encourage the use of cheaper biosimilars that can help patients and the health care system save big. They also learn what can be done to make very expensive gene therapies that provide a lot of value for patients more affordable and accessible....

SAN FRANCISCO – California’s surprise medical billing law (Assembly Bill 72) – which imposes price controls on the rates out-of-network physicians can charge at in-network facilities – is hurting patients with lower quality care, reduced access, and higher health care system costs, finds a new brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute. Click here to download the brief “California’s surprise medical billing law has created unintended consequences that are increasing healthcare costs and...

The Professor and Pete must collect 3 keys to finally escape the drug pricing maze.  The first key involves reforms to increase drug affordability for patients who buy their drugs at a pharmacy.  The Professor shows Pete that these reforms should ensure that prices are transparent, easy to understand, and help patients benefit from the large discounts that are being paid....

PRI senior fellow in health care studies Dr. Henry Miller joins "Next Round with PRI" to give an update on what scientists are learning about COVID-19 and the progress in finding a vaccine. He also weighs in on whether schools should be reopening this fall, gives his thoughts on what the Trump administration is doing good and bad in fighting the pandemic, and offers advices on how we can reduce our chances of getting the coronavirus. https://youtu.be/r8PCYOt_h5Y...

The Professor and Pete go to the movies to learn why there is a drug affordability problem. After watching a scary thriller about list prices and net prices, an adventure on the prescription escalator, and a movie on biosimilars, they learn that a) specific patient populations are impacted by the drug affordability problem; and b) these issues can be fixed with targeted reforms to achieve innovation and affordability....

Sally C. Pipes joined JT Nysewamder on Alabama Morning News in Birmingham to talk about the latest developments with the drug remdisivir. The drug, produced by Gilead, is being studied for potential use against COVID-19. Pipes and JT also discuss the cost of the drug, and how expensive it is to bring drugs to market in the United States. Listen to the interview here. ...